INV103:(X-Toll) pre-clinical results in lupus models
Strong pre-clinical data in lupus animal model (3 studies)
>significantly reduced kidney pathology
>improved survival
>prevented cutaneous lupus
>reduced renal and circulating levels of key pro-inflammatory mediators (TNF-a, IL-6 and MCP-1) reduced CD4+ T cells and auto-reactive T cells and increased the number of activated DC (critical in the establishment of self tolerance)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
-0.015(12.0%) |
Mkt cap ! $9.336M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 12.5¢ | 10.5¢ | $24.18K | 211.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 30000 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 28316 | 1 |
View Market Depth
| Last trade - 15.59pm 25/06/2025 (20 minute delay) ? |
| IVX (ASX) Chart |